Biopharmaceutical manufacturer.
H.R. 3982, the "Family Cord Blood Banking Act."
Policy issues relating to corporate tax reform. H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process. Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy.
H.R. 6, the 21st Century Cures Act.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2841, the Fair Access for Safe and Timely Generics Act.
H.R. 1600, the Patients Access to Treatments Act.
H.R. 2739, the Cancer Drug Coverage Parity Act.
S.1566, the "Cancer Drug Coverage Parity Act."
H.R. 3982, the Family Cord Blood Banking Act.
TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
FERGUSON STRATEGIES, LLC
801 Pennsylvania Ave NW, Suite 230, Washington, DC, 20004-2697, US
CHRIS JONES ADAM HIGGINS CHRIS JONES ADAM HIGGINS CHRIS JONES ADAM HIGGINS